A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression
Clinical trial NCT05215925 · UNKNOWN
Trial details
- NCT number
- NCT05215925
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-01
- Primary completion
- 2023-07-15
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.